Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug-Receptor Interaction: Antagonist

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Practicing the Art of Medicine in a Changing World.

Irish medical journal·2020

Same author

Benefits of pre-referral preparation for rheumatology clinics.

Irish medical journal·2014

Same author

Influenza and pneumococcal vaccination and varicella status in inflammatory arthritis patients.

Irish medical journal·2011

Same author

Clinical images: The iron salute: a sign of hemochromatosis.

Arthritis and rheumatism·2011

Same author

Synovial tissue hypoxia and inflammation in vivo.

Annals of the rheumatic diseases·2010

Same author

Unregulated prescribing of anti-tumour necrosis factor agents does not mean inappropriate prescribing.

Annals of the rheumatic diseases·2009

Same journal

Bridging the Divide in Global Rheumatology.

Rheumatic diseases clinics of North America·2026

Same journal

Foreword.

Rheumatic diseases clinics of North America·2026

Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026

Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026

Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026

Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Published on: March 1, 2011

Interleukin-1 receptor antagonist

B Bresnihan¹, G Cunnane

¹University College, Dublin, Ireland.

Rheumatic Diseases Clinics of North America

|August 26, 1998

Summary

This summary is machine-generated.

Interleukin-1 (IL-1) alpha and beta promote inflammation, while IL-1 receptor antagonist (IL-1ra) inhibits these effects. IL-1ra shows promise for treating inflammatory diseases like rheumatoid arthritis (RA).

More Related Videos

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

Published on: March 14, 2016

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Related Experiment Videos

Last Updated: Jun 16, 2026

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Published on: March 1, 2011

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

Published on: March 14, 2016

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Area of Science:

Immunology
Genetics
Rheumatology

Background:

The Interleukin-1 (IL-1) gene family includes IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist (IL-1ra).
IL-1 alpha and IL-1 beta are pro-inflammatory cytokines implicated in various inflammatory diseases.
IL-1ra acts as a natural inhibitor by blocking IL-1 receptors.

Purpose of the Study:

To explore the role of IL-1 family members in inflammatory processes.
To evaluate the therapeutic potential of IL-1ra in inflammatory conditions, particularly rheumatoid arthritis (RA).

Main Methods:

Analysis of the functions of IL-1 alpha, IL-1 beta, and IL-1ra.
Review of existing research on anti-IL-1 treatments in animal models and human RA.

Main Results:

IL-1 alpha and IL-1 beta exhibit significant pro-inflammatory activities.
IL-1ra effectively antagonizes the effects of IL-1 alpha and IL-1 beta.
Anti-IL-1 therapy has demonstrated positive outcomes in preclinical arthritis models and RA patients.

Conclusions:

IL-1 alpha and IL-1 beta are key players in the pathogenesis of inflammatory diseases.
IL-1ra represents a potential therapeutic strategy for managing inflammatory conditions such as RA.